Does Retatrutide Preserve Muscle? What the Body Composition Data Shows

The Lean Mass Question

Every pharmacological weight loss intervention faces the same fundamental concern: how much of the weight lost is fat, and how much is lean tissue — primarily skeletal muscle? This question has taken on particular urgency as GLP-1 receptor agonists have achieved weight loss magnitudes previously associated only with bariatric surgery, where lean mass preservation has been a longstanding clinical consideration.

For retatrutide, which produced 24.2% mean weight loss at the highest dose in Phase 2, the body composition question is especially pertinent. Losing nearly a quarter of body weight inevitably involves some lean mass reduction. The clinically relevant question is not whether lean mass loss occurs — it does with virtually every weight loss modality — but whether the proportion is acceptable and whether it compromises functional and metabolic outcomes.

The Phase 2 Body Composition Substudy

The Phase 2 retatrutide trial included a body composition substudy, published in The Lancet Diabetes & Endocrinology (Coskun et al., 2025), that used dual-energy X-ray absorptiometry (DEXA) scanning to quantify changes in fat mass and lean mass separately. DEXA is considered the clinical standard for body composition assessment, providing reliable differentiation between bone mineral content, fat tissue, and lean soft tissue.

At 48 weeks in the 12 mg dose group, the data demonstrated that approximately 75-80% of total weight lost was fat mass, with the remaining 20-25% attributable to lean mass reduction. This ratio — roughly three-quarters fat, one-quarter lean — represents a favorable body composition outcome for pharmacological weight loss.

Putting the Ratio in Context

To interpret the 75-80% fat loss ratio, it is useful to compare it against established benchmarks from other weight loss modalities.

With caloric restriction alone (diet-based weight loss without exercise), the typical ratio is approximately 75% fat and 25% lean mass. Adding resistance exercise to caloric restriction can improve this ratio modestly, to roughly 80-85% fat loss. Bariatric surgery, despite its superior total weight loss, generally shows a ratio of 70-80% fat loss depending on the procedure and time frame.

Among pharmacological agents, semaglutide 2.4 mg (Wegovy) has shown body composition data in the 75% range for fat mass as a proportion of total weight lost. Tirzepatide’s SURMOUNT program reported similar proportions, with approximately 75-80% of weight lost being fat mass at the highest doses.

Retatrutide’s ratio of 75-80% fat loss is therefore comparable to or slightly better than existing pharmacological agents, and consistent with what would be expected from a high-efficacy weight loss intervention. The data do not suggest that retatrutide causes disproportionate lean mass loss relative to other agents in the class.

The Glucagon Receptor Hypothesis

One mechanistic question of particular interest is whether retatrutide’s glucagon receptor component — the element that distinguishes it from dual agonists like tirzepatide — confers any advantage for body composition. The theoretical basis for this hypothesis rests on glucagon’s known metabolic effects.

Glucagon promotes hepatic and peripheral fat oxidation, effectively directing the body to preferentially metabolize lipid stores for energy. This pro-lipolytic effect could theoretically bias weight loss toward fat mass while relatively sparing lean tissue. Additionally, glucagon increases energy expenditure, which may reduce the degree of metabolic adaptation (the reduction in resting metabolic rate that typically accompanies weight loss) and thereby attenuate the physiological pressure to catabolize muscle for energy.

The Phase 2 body composition data are consistent with this hypothesis but do not prove it. The observed fat-to-lean loss ratio falls within the range seen with other high-efficacy agents, making it difficult to attribute any specific advantage to the glucagon component based on the available data. Demonstrating a mechanistic contribution of glucagon receptor agonism to lean mass preservation would require controlled comparisons — ideally, a head-to-head trial against a GLP-1/GIP dual agonist with matched total weight loss.

Absolute Versus Relative Lean Mass Loss

A nuanced point often lost in discussions of body composition is the distinction between relative and absolute lean mass changes. Even with a 20-25% lean mass proportion of total weight lost, the absolute amount of lean tissue reduction must be evaluated in the context of the individual’s total body composition.

Consider a participant starting at 120 kg who loses 24% of body weight (approximately 29 kg). If 22% of that weight loss is lean mass, the absolute lean mass reduction is roughly 6.4 kg. For an individual with a starting lean mass of approximately 55-65 kg (typical for someone at this weight), this represents a 10-12% reduction in lean tissue.

While not negligible, this level of lean mass reduction occurs alongside a dramatically larger reduction in fat mass (approximately 22.6 kg in this example). The net effect on body composition is a substantial improvement in the ratio of lean to fat tissue. The individual ends treatment with a higher percentage of lean body mass despite having lost some lean tissue in absolute terms.

This framing is important because it contextualizes lean mass loss as a component of an overall body composition improvement rather than an isolated adverse outcome.

Functional and Metabolic Implications

The clinical significance of lean mass loss depends on its functional consequences. Skeletal muscle is the primary determinant of resting metabolic rate, physical strength, mobility, and functional independence — particularly in older adults. Excessive lean mass loss could theoretically compromise these outcomes, undermining the long-term benefits of weight reduction.

The available evidence suggests that pharmacological weight loss at the magnitudes achieved by retatrutide does not produce clinically meaningful functional impairment in most patients. Phase 2 participants did not demonstrate disproportionate loss of physical function, though the trial was not specifically designed or powered to assess functional endpoints.

Importantly, the relationship between lean mass quantity and functional capacity is not strictly linear. A modest reduction in lean mass accompanied by a large reduction in fat mass may actually improve functional metrics such as mobility, exercise tolerance, and activities of daily living — because the mechanical burden of excess adiposity is reduced more than the muscular capacity to perform those activities.

What Phase 3 Will Add

The TRIUMPH Phase 3 program will include larger body composition analyses across more diverse populations and over longer treatment durations (68-72 weeks versus 48 weeks in Phase 2). These data will address several open questions.

First, whether the fat-to-lean loss ratio remains stable or shifts as treatment continues beyond 48 weeks. It is plausible that as the rate of weight loss decelerates in the later phases of treatment, the proportion of lean mass loss decreases — as has been observed in some bariatric surgery follow-up studies.

Second, whether specific subpopulations — older adults, those with lower baseline lean mass, or those with sarcopenic obesity — experience differential body composition outcomes. This information will be critical for clinical risk stratification and for determining whether adjunctive interventions such as resistance exercise or protein supplementation should be formally recommended alongside retatrutide treatment.

Third, whether the body composition changes correlate with functional assessments, metabolic rate measurements, and patient-reported outcomes in ways that inform clinical decision-making.

The Practical Takeaway

The Phase 2 body composition data indicate that retatrutide produces weight loss that is predominantly fat mass, at a ratio comparable to other high-efficacy pharmacological agents. The lean mass reduction, while real, is modest relative to the total body composition improvement. The glucagon receptor component may theoretically favor fat oxidation, though this has not been definitively demonstrated in comparative studies.

For clinical practice, these data support the position that lean mass loss during retatrutide treatment is a manageable consideration rather than a prohibitive concern — particularly when patients maintain adequate protein intake and engage in resistance exercise, interventions that have been shown to attenuate lean mass loss across weight management modalities.